

6 PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of the risk management plan for Otrafexi (fexofenadine hydrochloride)

This is a summary of the Risk Management Plan (RMP) for Otrafexi. The RMP details important risks of Otrafexi, and how more information will be obtained about Otrafexi's risks and uncertainties (missing information).

Otrafexi's summary of product characteristics (SmPC) gives essential information to healthcare professionals and patients on how fexofenadine hydrochloride should be used.

Important new concerns or changes to the current ones will be included in updates of Otrafexi's RMP.

I. The medicine and what it is used for

Otrafexi is authorised to be used in adults and children aged 12 years and above for the relief of symptoms associated with allergic rhinitis. It contains fexofenadine hydrochloride as the active substance, and it is given by oral administration.

II. Risks associated with the medicine and activities to minimise or further characterize the risks

Important risks of Otrafexi, together with measures to minimise such risks and the proposed studies for learning more about Otrafexi risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- important advice on the medicine's packaging;
- the authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- the medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analyzed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Otrafexi are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Otrafexi. Potential risks are concerns for which an

association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

Not Applicable.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Otrafexi.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Otrafexi.